Indian wellness startup K&L Wellness Technology receives start-up funding of $ 4 million
K&L Wellness Technology, a health technology startup in India, has bagged 30 billion rupees ($ 4 million) from angel investors to launch its wellness app.
According to a news report, the company wants to redefine wellness through science-based personalized solutions.
K&L Wellness, also known as RESET Tech, offers therapeutic health solutions for lifestyle problems using natural, sustainable and traditional methods of yoga and meditation.
The company plans to launch its wellness platform “early next quarter,” said co-founder Karan Talreja.
Vimal Kedia and Surendra Kedia from Manjushree Ventures and Narendra Firodia from Sohamm Group took part in the seed round.
Intellect extends free, limited-time access to self-care apps and resources
Intellect, a Singapore-based mental health startup, is offering a free six-month premium subscription to its self-care app and resources to customers and partners of the nonprofit Care Corner Singapore.
The offer is available now through the end of May next year and is aimed at Singapore’s middle and low income communities whose mental well-being has been severely affected by the ongoing COVID-19 pandemic. They also lack widespread access to affordable mental health care, according to Theodoric Chew, co-founder and CEO of Intellect.
Along with Care Corner’s customized mental health counseling services, Intellect will offer in-app modules and programs covering a range of topics such as basic mental health assistance, anxiety, worry, assertiveness and self-esteem. Some of these modules and programs include learning paths, rescue sessions, wellbeing check-in, analysis, and guided recordings.
Intellect will also give beneficiaries free access to its monthly series of webinars, Intellearn, and conduct online workshops to help users become familiar with its app and to help them integrate the learning paths and rescue sessions into their personal lives.
Lunit secures US FDA approvals for AI diagnostics for chest x-ray and mammography
South Korea-based medical AI provider Lunit has received 510 (k) approval from the U.S. Food and Drug Administration for its chest x-ray and mammography AI solutions.
Lunit INSIGHT MMG analyzes mammography images and detects the location of lesions indicative of breast cancer along with an abnormality score. This device will be trained on over 240,000 mammography cases, including approximately 50,000 breast cancer cases. It was previously approved in Europe after receiving a CE mark.
Meanwhile, Lunit INSIGHT CXR Triage is a triage and notification software that analyzes chest x-rays. It is designed to prioritize urgent cases such as pleural effusion and pneumothorax after examinations to quickly inform clinicians of findings, thereby reducing the diagnosis time for urgent cases. This device is trained with more than 160,000 chest x-rays with CT images. It showed a sensitivity of 94% to 96% and a specificity of 95% to 99% for pleural effusions and pneumothorax.
Sky Labs brings wearable heart monitor to the UK
South Korean medical technology startup Sky Labs is launching its AI-powered portable heart monitor called CART-I.
It has received CE-MDD approval in Europe, which allows the device to be used for atrial fibrillation monitoring and disease diagnosis in the region.
Sky Labs referred to the medical digitization in Great Britain, which triggered the “sharp growth” of the telemedicine and mobile health markets there and opened up an opportunity for the startup with the increasing interest in innovative health products.
The ring type CART-I automatically measures atrial fibrillation and heart rate around the clock. It uses EKG to capture precise heart signals and a PPG sensor for continuous monitoring of atrial fibrillation without intervention.
Collected data is transferred to a cloud platform, where it is processed by AI into findings and sent back to the user’s app as well as to the doctor’s platform. The data will help clinicians make an accurate diagnosis of their patients’ condition.
In June, Sky Labs received $ 20 million in a Series B investment round that was used to develop new monitoring devices for a variety of chronic diseases, gain market approvals, and recruit employees.
Terumo and Diabeloop Sign Contract to Deliver Automated Insulin Delivery Solutions to Europe
Terumo Corporation, a Tokyo-based medical device company, and French therapeutic AI treatment device maker Diabeloop have teamed up to expand their solutions for diabetics in Europe.
They agreed to commercialize their automated insulin delivery system (AID) with potential for further global expansion.
The AID system is used for insulin-dependent diabetes management and automates and personalizes the treatment of diabetes. A self-learning algorithm developed by Diabeloop called DBLG1 is connected to a continuous glucose monitor and a Terumo insulin pump. It analyzes data in real time and can either keep current insulin settings or adjust insulin delivery.
The two companies have been developing the AID system since 2020 with the primary goal of targeting Japanese patients.
“Together with Diabeloop, we are confident that we can deliver value-added solutions to healthcare professionals and patients not just in Japan but around the world,” said Hikaru Samejima, President of Terumo’s General Hospital Company.
“We are pleased to strengthen our partnership with world market leader Terumo with this new agreement and to expand our contribution to personalized diabetes management through Diabeloop’s interoperable solution,” said Marc Julien, Co-CEO of Diabeloop.
US-based Labcorp opens bioanalytical laboratory in Singapore
The American life science company Labcorp has opened an integrated bioanalytical laboratory in Singapore.
Its newest facility in the Asia Pacific region, along with the company’s central laboratory services and clinical development and commercialization services, will strengthen its laboratory network in the region.
According to a press release, the new bioanalytical laboratory will offer bioanalysis, liquid chromatography-mass spectrometry and immunochemistry platforms, as well as clinical biomarker analysis services.
The all-in-one facility will provide customers with “faster turnaround times” for data in early-stage studies being conducted in the region, said Dr. Paul Kirchgraber, CEO of Labcorp Drug Development.
“Singapore serves as a strategic location from which Labcorp can increase accessibility by providing regional and international customers with comprehensive support for their bioanalytical studies,” said Kirchgraber.